Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer

被引：104

作者：

Ali, Omar Hasan ^{[1
,2
]}

Diem, Stefan ^{[3
,4
]}

Markert, Eva ^{[5
]}

Jochum, Wolfram ^{[5
]}

Kerl, Katrin ^{[6
]}

French, Lars E. ^{[6
]}

Speiser, Daniel E. ^{[7
]}

Fruh, Martin ^{[3
]}

Flatz, Lukas ^{[1
,2
,6
]}

机构：

[1] Cantonal Hosp St Gallen, Dept Dermatol & Allergol, St Gallen, Switzerland

[2] Cantonal Hosp St Gallen, Inst Immunobiol, St Gallen, Switzerland

[3] Cantonal Hosp St Gallen, Dept Oncol & Hematol, St Gallen, Switzerland

[4] Hosp Grabs, Dept Oncol & Hematol, Grabs, Switzerland

[5] Cantonal Hosp St Gallen, Inst Pathol, St Gallen, Switzerland

[6] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[7] Univ Lausanne, Dept Oncol & Ludwig Canc Res, Lausanne, Switzerland

来源：

OncoImmunology | 2016年 / 5卷 / 11期

基金：

瑞士国家科学基金会;

关键词：

Anti-PD1; histology; immunotherapy; non-small cell lung cancer; skin eruption; CUTANEOUS ADVERSE EVENTS; UNTREATED MELANOMA; THERAPY; MONOTHERAPY; DOCETAXEL; SAFETY; TRIAL;

D O I：

10.1080/2162402X.2016.1231292

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, we retrospectively investigated immune-related adverse skin reactions (irAEs) in 40 patients with metastatic NSCLC treated with the anti-PD-1 antibody nivolumab. 7 out of 40 patients (17%) developed an irAEs. Skin irAEs correlated with tumor responses in 5 of 12 responders (42%) as compared to 2 of 27 non-responders (7%). Histologically, scaly plaques showed dermatitis consisting mainly of lymphocytes. We observed a positive correlation between skin irAEs and tumor responses in patients with NSCLC treated with nivolumab. Patterns of lymphocytic skin infiltration differed depending on the histological tumor subtype (adenocarcinoma versus squamous cell carcinoma NSCLC).

引用

页数：5

共 19 条

[1]

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[4]

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes [J].

Freeman-Keller, Morganna ;

Kim, Youngchul ;

Cronin, Heather ;

Richards, Allison ;

Gibney, Geoffrey ;

Weber, Jeffrey S. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :886-894

[5]

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott ;

Rizvi, Naiyer A. ;

Chow, Laura Q. ;

Borghaei, Hossein ;

Brahmer, Julie ;

Ready, Neal ;

Gerber, David E. ;

Shepherd, Frances A. ;

Antonia, Scott ;

Goldman, JonathanW. ;

Juergens, Rosalyn A. ;

Laurie, Scott A. ;

Nathan, Faith E. ;

Shen, Yun ;

Harbison, Christopher T. ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) :2980-+

[6]

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy [J].

Goldinger, Simone M. ;

Stieger, Pascale ;

Meier, Barbara ;

Micaletto, Sara ;

Contassot, Emmanuel ;

French, Lars E. ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2016, 22 (16) :4023-4029

[7]

Hanna Jennifer M, 2013, J Carcinog, V12, P6, DOI 10.4103/1477-3163.109033

[8]

Reassessing target antigens for adoptive T-cell therapy [J].

Hinrichs, Christian S. ;

Restifo, Nicholas P. .

NATURE BIOTECHNOLOGY, 2013, 31 (11) :999-1008

[9]

Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]

[10]

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy [J].

Lo, Jennifer A. ;

Fisher, David E. ;

Flaherty, Keith T. .

JAMA ONCOLOGY, 2015, 1 (09) :1340-+

← 1 2 →